{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:19:17Z","timestamp":1783743557975,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtha.2025.09.029","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:18:43Z","timestamp":1760804323000},"page":"132-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial"],"prefix":"10.1016","volume":"24","author":[{"given":"Kaan","family":"Kavakli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaan-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine N.","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazzaa","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Rupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Biondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Agathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Plonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"von Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.029_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib2","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/hae.13596","article-title":"Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B","volume":"24","author":"Booth","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","article-title":"Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2025.09.029_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hae.14525","article-title":"Quality of life in a large multinational haemophilia B cohort (the B-Natural study) \u2013 unmet needs remain","volume":"28","author":"Berntorp","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/hae.14759","article-title":"No difference in quality of life between persons with severe haemophilia A and B","volume":"29","author":"Kihlberg","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-022-02301-0","article-title":"Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study","volume":"17","author":"Rodriguez-Santana","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2025.09.029_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/jcm6070063","article-title":"Pathophysiology of hemophilic arthropathy","volume":"6","author":"Melchiorre","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.09.029_bib8","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","article-title":"Health care resource utilization and cost burden of hemophilia B in the United States","volume":"5","author":"Buckner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.09.029_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.029_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.12239","article-title":"Haemophilia Experiences, Results and Opportunities (HERO) study: survey methodology and population demographics","volume":"20","author":"Forsyth","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2025.09.029_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.13027","article-title":"Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.09.029_bib13","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jpain.2021.03.157","article-title":"Prevalence and interference of chronic pain among people with hemophilia: a systematic review and meta-analysis","volume":"22","author":"Paredes","year":"2021","journal-title":"J Pain"},{"key":"10.1016\/j.jtha.2025.09.029_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2516.2006.01203.x","article-title":"Pain and functional limitations in patients with severe haemophilia","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/hae.13214","article-title":"Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study","volume":"23","author":"Witkop","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib16","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.13548","article-title":"Emotional distress in haemophilia: factors associated with the presence of anxiety and depression symptoms among adults","volume":"24","author":"Pinto","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.13025","article-title":"Factors associated with pain severity, pain interference, and perception of functional abilities independent of joint status in US adults with hemophilia: multivariable analysis of the Pain, Functional Impairment, and Quality of Life (P-FiQ) study","volume":"100","author":"Kempton","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.09.029_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2025.09.029_bib19","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.029_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hae.14675","article-title":"Association of factor expression levels with annual bleeding rate in people with haemophilia B","volume":"29","author":"Burke","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","article-title":"Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B","volume":"22","author":"Kavakli","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.12228","article-title":"Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I\/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level \u22642%) haemophilia B","volume":"20","author":"Windyga","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.029_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib25","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41687-023-00550-6","article-title":"Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)","volume":"7","author":"Brod","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jtha.2025.09.029_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jtha.2025.09.029_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.029_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/hae.14167","article-title":"Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.029_bib35","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.029_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.029_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13023-024-03181-2","article-title":"A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: insights from the physician, the nurse and the patient","volume":"19","author":"Miesbach","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2025.09.029_bib38","article-title":"Gene therapy in hemophilia: a transformational patient experience","volume":"10","author":"Rasul","year":"2023","journal-title":"J Patient Exp"},{"key":"10.1016\/j.jtha.2025.09.029_bib39","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood.V104.11.2214.2214","article-title":"Development and pilot testing of a disease-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL) [abstract]","volume":"104","author":"v. Mackensen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib40","series-title":"Handbook of disease burdens and quality of life measures","first-page":"1895","article-title":"Quality of life in hemophilia","author":"Von Mackensen","year":"2010"},{"key":"10.1016\/j.jtha.2025.09.029_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.13140","article-title":"Measurement properties of the Haem-A-QoL in haemophilia clinical trials","volume":"23","author":"von Mackensen","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hae.14184","article-title":"Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL)","volume":"26","author":"von Mackensen","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2516.2006.01186.x","article-title":"Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hae.14226","article-title":"Assessing the test-retest reliability and smallest detectable change of the Haemophilia Activities List","volume":"27","author":"Kuijlaars","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib45","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jtha.2025.09.029_bib46","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jtha.2025.09.029_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \u201chemophilia-free mind\u201d\u2014the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.029_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtha.2025.09.029_bib50","series-title":"Self-reported population health: an international perspective based on EQ-5D","first-page":"19","article-title":"Population norms for the EQ-5D","author":"Janssen","year":"2014"},{"key":"10.1016\/j.jtha.2025.09.029_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O'Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib52","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"Oladapo","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib53","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood-2012-12-470898","article-title":"Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s","volume":"122","author":"Fischer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib54","author":"Itzler"},{"key":"10.1016\/j.jtha.2025.09.029_bib55","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.029_bib56","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2023-179431","article-title":"Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec [abstract]","volume":"142","author":"von Mackensen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.029_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.17225\/jhp00176","article-title":"The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia","volume":"8","author":"Bullinger","year":"2021","journal-title":"J Haemophilia Pract"},{"key":"10.1016\/j.jtha.2025.09.029_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jtha.2025.09.029_bib59","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.jtha.2025.09.029_bib60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jtha.2025.09.029_bib61","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2014.07.003","article-title":"Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE)","volume":"17","author":"Recht","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2025.09.029_bib62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.029_bib63","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1111\/hae.12748","article-title":"Distress in patients with bleeding disorders: a single institutional cross-sectional study","volume":"21","author":"Barry","year":"2015","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:05:55Z","timestamp":1768464355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538783625006488"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Pfizer Inc. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}